litlas
Log inCreate account

Kevan C. Herold

Active 1983–2025

Also published as
Kevan C Herold
156
Papers
28,477
Citations
91
h-index
148
i10-index

Citations

Citations per year for Kevan C. Herold1984: 2 citations1985: 4 citations1986: 6 citations1987: 4 citations1988: 11 citations1989: 1 citations1990: 7 citations1991: 7 citations1992: 2 citations1993: 1 citations1994: 4 citations1995: 16 citations1996: 26 citations1997: 28 citations1998: 33 citations1999: 40 citations2000: 37 citations2001: 27 citations2002: 40 citations2003: 40 citations2004: 59 citations2005: 68 citations2006: 85 citations2007: 105 citations2008: 139 citations2009: 162 citations2010: 146 citations2011: 134 citations2012: 208 citations2013: 270 citations2014: 186 citations2015: 241 citations2016: 230 citations2017: 244 citations2018: 268 citations2019: 856 citations2020: 991 citations2021: 1,195 citations2022: 977 citations2023: 898 citations2024: 1,398 citations2025: 815 citations2026: 15 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,136 citing papers, 30.3% of this breakdownChina: 829 citing papers, 8% of this breakdownUnited Kingdom: 768 citing papers, 7.4% of this breakdownGermany: 631 citing papers, 6.1% of this breakdownItaly: 455 citing papers, 4.4% of this breakdownCanada: 400 citing papers, 3.9% of this breakdownAustralia: 339 citing papers, 3.3% of this breakdownFrance: 329 citing papers, 3.2% of this breakdownJapan: 253 citing papers, 2.5% of this breakdownSweden: 247 citing papers, 2.4% of this breakdownNetherlands: 231 citing papers, 2.2% of this breakdownBelgium: 217 citing papers, 2.1% of this breakdown
0%30.3%Other 24.2%

Institutions

Fields

  • Medicine44.6%
  • Biochemistry, Genetics and Molecular Biology34.4%
  • Immunology and Microbiology16.1%
  • Neuroscience1.3%
  • Nursing1.1%
  • Engineering0.6%
  • Other1.9%

Topics

  • Diabetes and associated disorders10.6%
  • Pancreatic function and diabetes8.7%
  • Diabetes Management and Research6.4%
  • Immune Cell Function and Interaction6.2%
  • T-cell and B-cell Immunology5.8%
  • CAR-T cell therapy research3.3%
  • Other59%

Coauthors

All papers

Open in search
  1. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

    Authors: Kevan C. Herold, Brian N. Bundy, S. Alice Long, Jeffrey A. Bluestone, Linda A. DiMeglio, Matthew J. Dufort, Stephen E. Gitelman, Peter A. Gottlieb, Jeffrey P. Krischer, Peter S. Linsley, Jennifer B. Marks, Wayne D. Moore, Antoinette Moran, Henry Rodriguez, William E. Russell, Desmond Schatz, Jay S. Skyler, Eva Tsalikian, Diane K. Wherrett, Anette-Gabriele Ziegler, Carla J. Greenbaum - New England Journal of Medicine 2019 cited by 1,112

  2. Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association

    Authors: Richard A. Insel, Jessica L. Dunne, Mark A. Atkinson, Jane L. Chiang, Dana Dabelea, Peter A. Gottlieb, Carla J. Greenbaum, Kevan C. Herold, Jeffrey P. Krischer, Åke Lernmark, Robert E. Ratner, Marian Rewers, Desmond Schatz, Jay S. Skyler, Jay M. Sosenko, Anette‐G. Ziegler - Diabetes Care 2015 cited by 1,148

  3. Type 1 diabetes immunotherapy using polyclonal regulatory T cells

    Authors: Jeffrey A. Bluestone, Jane H. Buckner, Mark Fitch, Stephen E. Gitelman, Shipra Gupta, Marc K. Hellerstein, Kevan C. Herold, Angela Lares, Michael R. F. Lee, Kelvin Li, Weihong Liu, S. Alice Long, Lisa M. Masiello, Vinh Nguyen, Amy Putnam, Mary Rieck, Peter H. Sayre, Qizhi Tang - Science Translational Medicine 2015 cited by 1,013

  4. Reprogramming human T cell function and specificity with non-viral genome targeting

    Authors: Theodore L. Roth, Cristina Puig-Saus, Ruby Yu, Eric Shifrut, Julia Carnevale, P. Jonathan Li, Joseph Hiatt, Justin D. Saco, Paige Krystofinski, Han Li, Victoria Tobin, David N. Nguyen, Michael R. Lee, Amy Putnam, Andrea L. Ferris, Jeff W. Chen, Jean-Nicolas Schickel, Laurence Pellerin, David Carmody, Gorka Alkorta‐Aranburu, Daniela del Gaudio, Hiroyuki Matsumoto, Montse Morell, Ying Mao, Min Cho, Rolen M. Quadros, Channabasavaiah B. Gurumurthy, Baz Smith, Michael Haugwitz, Stephen H. Hughes, Jonathan S. Weissman, Kathrin Schumann, Jonathan H. Esensten, Andrew P. May, Alan Ashworth, Gary M. Kupfer, Siri Atma W. Greeley, Rosa Bacchetta, Eric Meffre, Maria Grazia Roncarolo, Neil Romberg, Kevan C. Herold, Antoni Ribas, Manuel D. Leonetti, Alexander Marson - Nature 2018 cited by 871

  5. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals

    Authors: Emily K. Sims, Brian N. Bundy, Kenneth Stier, Elisavet Serti, Noha Lim, S. Alice Long, Susan Geyer, Antoinette Moran, Carla J. Greenbaum, Carmella Evans‐Molina, Kevan C. Herold, Type 1 Diabetes TrialNet Study Group, Linda A. DiMeglio, Stephen E. Gitelman, Peter A. Gottlieb, Jennifer B. Marks, Wayne D. Moore, Henry Rodriguez, William E. Russell, Desmond Schatz, Eva Tsalikian, Diane K. Wherrett, Anette‐Gabriele Ziegler - Science Translational Medicine 2021 cited by 359

  6. Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes

    Authors: Eleanor L. Ramos, Colin Dayan, Lucienne Chatenoud, Zdenĕk Šumnı́k, Kimber M. Simmons, Agnieszka Szypowska, Stephen E. Gitelman, Laura A. Knecht, Elisabeth Niemoeller, Wei Tian, Kevan C. Herold - New England Journal of Medicine 2023 cited by 234

  7. Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective

    Authors: Emily K. Sims, Rachel Besser, Colin Dayan, Cristy Geno Rasmussen, Carla J. Greenbaum, Kurt Griffin, William Hagopian, Mikael Knip, Anna E. Long, Frank B. Martin, Chantal Mathieu, Marian Rewers, Andrea K. Steck, John M. Wentworth, Stephen S. Rich, Olga Kordonouri, Anette‐Gabriele Ziegler, Kevan C. Herold, for the NIDDK Type 1 Diabetes TrialNet Study Group - Diabetes 2022 cited by 230

  8. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes

    Authors: Shen Dong, Kamir J. Hiam-Galvez, Cody T. Mowery, Kevan C. Herold, Stephen E. Gitelman, Jonathan H. Esensten, Weihong Liu, Angela Lares, Ashley Leinbach, Michael Lee, Vinh Nguyen, Stanley Tamaki, Whitney Tamaki, Courtney Tamaki, Morvarid Mehdizadeh, Amy Putnam, Matthew H. Spitzer, Chun Ye, Qizhi Tang, Jeffrey A. Bluestone - JCI Insight 2021 cited by 221

  9. Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors

    Authors: Angeliki M. Stamatouli, Zoe Quandt, Ana Luisa Perdigoto, Pamela Clark, Harriet M. Kluger, Sarah A. Weiss, Scott Gettinger, Mario Sznol, Arabella Young, Robert J Rushakoff, James Lee, Jeffrey A. Bluestone, Mark S. Anderson, Kevan C. Herold - Diabetes 2018 cited by 575

  10. Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes

    Authors: Manuela Battaglia, Simi Ahmed, Mark S. Anderson, Mark A. Atkinson, Dorothy Becker, Polly J. Bingley, Emanuele Bosi, Todd M. Brusko, Linda A. DiMeglio, Carmella Evans‐Molina, Stephen E. Gitelman, Carla J. Greenbaum, Peter A. Gottlieb, Kevan C. Herold, Martin J. Hessner, Mikael Knip, Laura M. Jacobsen, Jeffrey P. Krischer, S. Alice Long, Markus Lundgren, Eoin McKinney, Noel G. Morgan, Richard A. Oram, Tomi Pastinen, Michael C. Peters, Alessandra Petrelli, Xiaoning Qian, María J. Redondo, Bart O. Roep, Desmond Schatz, David Skibinski, Mark Peakman - Diabetes Care 2019 cited by 344

  11. The immunology of type 1 diabetes

    Authors: Kevan C. Herold, Thomas Delong, Ana Luisa Perdigoto, Noah Biru, Todd M. Brusko, Lucy S. K. Walker - Nature reviews. Immunology 2024 cited by 190

  12. Immunotherapy: Building a bridge to a cure for type 1 diabetes

    Authors: Jeffrey A. Bluestone, Jane H. Buckner, Kevan C. Herold - Science 2021 cited by 214

  13. Genetics, pathogenesis and clinical interventions in type 1 diabetes

    Authors: Jeffrey A. Bluestone, Kevan C. Herold, George S. Eisenbarth - Nature 2010 cited by 1,266

  14. Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial

    Authors: Kevan C. Herold, Stephen E. Gitelman, Mario R. Ehlers, Peter A. Gottlieb, Carla J. Greenbaum, William Hagopian, Karen D. Boyle, Lynette Keyes-Elstein, Sudeepta Aggarwal, Deborah Phippard, Peter H. Sayre, James McNamara, Jeffrey A. Bluestone, and the AbATE Study Team - Diabetes 2013 cited by 405

  15. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial

    Authors: William E. Russell, Brian N. Bundy, Mark S. Anderson, Laura A. Cooney, Stephen E. Gitelman, Robin Goland, Peter A. Gottlieb, Carla J. Greenbaum, Michael J. Haller, Jeffrey P. Krischer, Ingrid Libman, Peter S. Linsley, S. Alice Long, Sandra Lord, Daniel J. Moore, Wayne V. Moore, Antoinette Moran, Andrew Muir, Philip Raskin, Jay S. Skyler, John M. Wentworth, Diane K. Wherrett, Darrell M. Wilson, Anette‐Gabriele Ziegler, Kevan C. Herold, Type 1 Diabetes TrialNet Study Group - Diabetes Care 2023 cited by 96

  16. Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function

    Authors: Kevan C. Herold, Stephen E. Gitelman, Peter A. Gottlieb, Laura A. Knecht, Ralph Raymond, Eleanor L. Ramos - Diabetes Care 2023 cited by 123

  17. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

    Authors: Nicole Sherry, William Hagopian, Johnny Ludvigsson, Sunil Kumar, Jack Wahlen, Robert J. Ferry, Bruce W. Bode, Stephen Aronoff, Christopher M. Holland, David A Carlin, Karen L. King, Ronald L. Wilder, Stanley R. Pillemer, Ezio Bonvini, Syd Johnson, Kathryn E. Stein, Scott Koenig, Kevan C. Herold, Anastasia G. Daifotis - The Lancet 2011 cited by 489

  18. Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes

    Authors: S. Alice Long, Jerill Thorpe, Hannah A. DeBerg, Vivian H. Gersuk, James A. Eddy, Kristina M. Harris, Mario R. Ehlers, Kevan C. Herold, Gerald T. Nepom, Peter S. Linsley - Science Immunology 2016 cited by 249

  19. Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes

    Authors: Michael J. Haller, Desmond Schatz, Jay S. Skyler, Jeffrey P. Krischer, Brian N. Bundy, Jessica Miller, Mark A. Atkinson, Dorothy J. Becker, David A. Baidal, Linda A. DiMeglio, Stephen E. Gitelman, Robin Goland, Peter A. Gottlieb, Kevan C. Herold, Jennifer B. Marks, Antoinette Moran, Henry Rodriguez, William E. Russell, Darrell M. Wilson, Carla J. Greenbaum, Type 1 Diabetes TrialNet ATG-GCSF Study Group, Carla J. Greenbaum, Mark A. Atkinson, David A. Baidal, M. Battaglia, Dorothy Becker, P. J. Bingley, Emanuele Bosi, Jan C. Buckner, Mark A. Clements, Peter G. Colman, Linda A. DiMeglio, Carmella Evans‐Molina, Stephen E. Gitelman, Robin Goland, Peter A. Gottlieb, Kevan C. Herold, Mikael Knip, J. Krischer, Åke Lernmark, W. Moore, Antoinette Moran, Andrew J. Muir, J. Palmer, Mark Peakman, Louis H. Philipson, Philip Raskin, María J. Redondo, Henry Rodriguez, W. J. Russell, Lisa M. Spain, Desmond Schatz, Jay M. Sosenko, Diane K. Wherrett, Darrell M. Wilson, William E. Winter, Anette‐Gabriele Ziegler, Mark S. Anderson, Peter A. Antinozzi, Christophe Benoıst, J.J. Blum, Kasia Bourcier, Peter Chase, Michael Clare‐Salzler, Raphael Clynes, Catherine C. Cowie, George S. Eisenbarth, C. Garrison Fathman, Gilman D. Grave, L. Harrison, Bernhard J. Hering, Richard A. Insel, Sabine D. Jordan, Francine Kaufman, Tom Kay, Norma S. Kenyon, R. Klines, John M. Lachin, Ellen Leschek, Jeff Mahon, Jennifer B. Marks, Roshanak Monzavi, Kirsti Näntö‐Salonen, Gerald T. Nepom, Tihamer Orban, Robertson Parkman, Mark D. Pescovitz, John Peyman, A. Pugliese, John A. Ridge, Bart O. Roep, Maria Grazia Roncarolo, Peter J. Savage, Olli Simell, R S Sherwin, Mark Siegelman, Jay S. Skyler, Andrea K. Steck, James W. Thomas, Massimo Trucco and 212 more - Diabetes Care 2018 cited by 180

  20. Control of TH17 cells occurs in the small intestine

    Authors: Enric Esplugues, Samuel Huber, Nicola Gagliani, Anja E. Hauser, Terrence Town, Yisong Y. Wan, William O’Connor, Anthony Rongvaux, Nico van Rooijen, Ann M. Haberman, Yoichiro Iwakura, Vijay K. Kuchroo, Jay K. Kolls, Jeffrey A. Bluestone, Kevan C. Herold, Richard A. Flavell - Nature 2011 cited by 661

  21. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

    Authors: Antoinette Moran, Brian N. Bundy, Dorothy Becker, Linda A. DiMeglio, Stephen E. Gitelman, Robin Goland, Carla J. Greenbaum, Kevan C. Herold, Jennifer B. Marks, Philip Raskin, Srinath Sanda, Desmond Schatz, Diane K. Wherrett, Darrell M. Wilson, Jeffrey P. Krischer, Jay S. Skyler, Linda Pickersgill, Eelco J.P. de Koning, Anette‐G. Ziegler, Bernhard O. Boehm, Klaus Badenhoop, Nanette C. Schloot, J. F. Bak, Paolo Pozzilli, Dı́dac Mauricio, Marc Y. Donath, Luís Castaño, Ana M. Wägner, H. H. Lervang, Hans Perrild, Thomas Mandrup‐Poulsen - The Lancet 2013 cited by 354

  22. Sodium chloride inhibits the suppressive function of FOXP3+ regulatory T cells

    Authors: Amanda Hernandez, Alexandra Kitz, Chuan Wu, Daniel E. Lowther, Donald M. Rodriguez, Nalini Vudattu, Songyan Deng, Kevan C. Herold, Vijay K. Kuchroo, Markus Kleinewietfeld, David A. Hafler - Journal of Clinical Investigation 2015 cited by 332

  23. A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk

    Authors: María J. Redondo, Susan Geyer, Andrea K. Steck, Seth A. Sharp, John M. Wentworth, Michael N. Weedon, Peter A. Antinozzi, Jay M. Sosenko, Mark A. Atkinson, Alberto Pugliese, Richard A. Oram, Type 1 Diabetes TrialNet Study Group, Peter A. Antinozzi, Mark A. Atkinson, Manuela Battaglia, Dorothy J. Becker, P. J. Bingley, Emanuele Bosi, Jan C. Buckner, Peter G. Colman, Peter A. Gottlieb, Kevan C. Herold, Richard A. Insel, Tom Kay, Mikael Knip, Jennifer B. Marks, Antoinette Moran, James L. Palmer, Mark Peakman, Louis H. Philipson, Alberto Pugliese, P. Raskin, Henry Rodriguez, Bart O. Roep, William E. Russell, Desmond Schatz, Diane K. Wherrett, Darrell M. Wilson, William E. Winter, Anette‐Gabriele Ziegler, Christophe Benoıst, J.J. Blum, Peter Chase, Michael Clare‐Salzler, Raphael Clynes, George S. Eisenbarth, C. Garrison Fathman, Gilman D. Grave, Bernhard J. Hering, Francine Kaufman, Ellen Leschek, J. Mahon, Kirsti Näntö‐Salonen, Gerald T. Nepom, Tihamer Orban, Robertson Parkman, Mark D. Pescovitz, John Peyman, Maria Grazia Roncarolo, Olli Simell, Robert Sherwin, Mark Siegelman, Andrea K. Steck, James W. Thomas, Massimo Trucco, J. Richard Wagner, Carla J. Greenbaum, Katarzyna Bourcier, Richard A. Insel, Jeffrey P. Krischer, Ellen Leschek, Lisa Rafkin, Lisa M. Spain, Catherine C. Cowie, Mary A. Foulkes, Heidi Krause‐Steinrauf, John M. Lachin, Saúl Malozowski, John Peyman, J P Ridge, Peter J. Savage, Jay S. Skyler, Stephanie J. Zafonte, Norma S. Kenyon, Irene Santiago, Jay M. Sosenko, Brian N. Bundy, Michael Abbondondolo, Timothy E. Adams, Darlene Amado, Ilma Asif, Matthew Boonstra, Brian N. Bundy, Cristina Burroughs, David Cuthbertson, Mary Deemer, Christopher Eberhard, Steve Fiske, Julie Ford, Jennifer Garmeson and 1,520 more - Diabetes Care 2018 cited by 169

  24. Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus

    Authors: Kevan C. Herold, William Hagopian, Julie Auger, Ena Poumian-Ruiz, Lesley Taylor, David Donaldson, Stephen E. Gitelman, David M. Harlan, Danlin Xu, Robert A. Zivin, Jeffrey A. Bluestone - New England Journal of Medicine 2002 cited by 1,215